Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats

Texto completo
Autor(es):
Mostrar menos -
Cezar, Marcelo D. M. [1] ; Damatto, Ricardo L. [1] ; Pagan, Luana U. [1] ; Lima, Aline R. R. [1] ; Martinez, Paula F. [2] ; Bonomo, Camila [1] ; Rosa, Camila M. [1] ; Campos, Dijon H. S. [1] ; Cicogna, Antonio C. [1] ; Gomes, Mariana J. [1] ; Oliveira-, Jr., Silvio A. [2] ; Blotta, Daniella A. [1] ; Okoshi, Marina P. [1] ; Okoshi, Katashi [1]
Número total de Autores: 14
Afiliação do(s) autor(es):
[1] Sao Paulo State Univ, UNESP, Botucatu Med Sch, Dept Internal Med, Botucatu, SP - Brazil
[2] Univ Fed Mato Grosso do Sul, Campo Grande - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: CELLULAR PHYSIOLOGY AND BIOCHEMISTRY; v. 36, n. 4, p. 1453-1466, 2015.
Citações Web of Science: 20
Resumo

Background: We evaluated the role of the aldosterone blocker spironolactone in attenuating long-term pressure overload-induced cardiac remodeling and heart failure (HF) in spontaneously hypertensive rats (SHR). Methods and Results: Thirteen month-old male SHR were assigned to control (SHR-C, n=20) or spironolactone (SHR-SPR, 20 mg/kg/day, n=24) groups for six months. Normotensive Wistar-Kyoto rats (WKY, n=15) were used as controls. Systolic blood pressure was higher in SHR groups and unchanged by spironolactone. Right ventricular hypertrophy, which characterizes HF in SHR, was less frequent in SHR-SPR than SHR-C. Echocardiographic parameters did not differ between SHR groups. Myocardial function was improved in SHR-SPR compared to SHR-C {[}developed tension: WKY 4.85 +/- 0.68; SHR-C 5.22 +/- 1.64; SHR-SPR 6.80 +/- 1.49 g/mm(2); -dT/dt: WKY 18.0 (16.0-19.0); SHR-C 20.8 (18.4-25.1); SHR-SPR 28.9 (24.2-34.6) g/mm(2)/s]. Cardiomyocyte cross-sectional area and total collagen concentration (WKY 1.06 +/- 0.34; SHR-C 1.85 +/- 0.63; SHR-SPR 1.28 +/- 0.39 mu g/mg wet tissue) were greater in SHR-C than WKY and SHR-SPR. Type 3 collagen expression was lower in SHR-C than WKY and unchanged by spironolactone. Soluble collagen, type I collagen, and lysyl oxidase did not differ between groups. Conclusion: Early spironolactone treatment decreases heart failure development frequency by improving myocardial systolic and diastolic function and attenuating hypertrophy and fibrosis in spontaneously hypertensive rats. Copyright (C) 2015 S. Karger AG, Basel (AU)

Processo FAPESP: 09/54407-9 - Efeitos do bloqueio precoce da aldosterona na estrutura e funcao cardiaca e na composicao da matriz colagena miocardica de ratos espontaneamente hipertensos.
Beneficiário:Marcelo Diarcadia Mariano Cezar
Modalidade de apoio: Bolsas no Brasil - Doutorado
Processo FAPESP: 09/54102-3 - EMU: aquisição de ultracentrífuga e ecocardiógrafo para equipar Laboratório Multiusuário Centralizado
Beneficiário:Marina Politi Okoshi
Modalidade de apoio: Auxílio à Pesquisa - Programa Equipamentos Multiusuários
Processo FAPESP: 09/54506-7 - Efeitos do bloqueio precoce da aldosterona na estrutura e funcao cardiaca e na composicao da matriz colagena miocardica de ratos espontaneamente hipertensos.
Beneficiário:Katashi Okoshi
Modalidade de apoio: Auxílio à Pesquisa - Regular